AM 1030

Drug Profile

AM 1030

Alternative Names: AM1030; AM1030-CREAM

Latest Information Update: 13 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AnaMar AB
  • Developer AnaMar AB; Covance
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Atopic dermatitis

Most Recent Events

  • 11 Aug 2015 AnaMar AB completes a phase I/II trial for Atopic dermatitis in the United Kingdom
  • 03 Feb 2015 AM 1030 is available for licensing as of 03 Feb 2015.
  • 01 Nov 2014 Phase-I/II clinical trials in Atopic dermatitis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top